Health Ministry places Pregabalin under schedule H1 regulations to limit unauthorized consumption

The Health Ministry integrated the medication Pregabalin under stringent schedule H1 drug regulations to curb rising instances of substance misuse. This regulatory update requires retail chemists and licensed pharmacies to maintain detailed records of every sale, including prescriber details and patient identification information. The intervention restricts the unrestricted availability of the pharmaceutical compound across retail distribution networks. Schedule H1 regulations function as a specialized containment mechanism designed to monitor high-risk prescription drugs that are prone to dependency and chemical abuse.

Under previous classification norms, dispensing controls were less rigorous, allowing broader distribution without mandatory audit trails at the retail level. Implementing strict dispensing protocols forces pharmacies to maintain physical or digital registers, ensuring accountability and traceability across the medical supply chain. Pharmacists, healthcare providers, and compliance auditors must update their record-keeping systems and verify prescription validity before dispensing the medication.

Businesses must track official gazette notifications for compliance timelines and ensure staff are trained on schedule H1 documentation mandates. Maintaining meticulous sales registers protects establishments from regulatory penalties and supports public health objectives regarding controlled substance distribution.